Swedish Orphan Biovitrum appoints president and ceo

Geoffrey McDonough takes the role, joining the firm from Genzyme

Geoffrey McDonough, currently Genzyme’s president of Europe, Middle East and Africa (EMEA), will move Swedish Orphan Biovitrum (Sobi) as president and ceo on 15 August. He will succeed Kennet Rooth, who has been acting ceo since the beginning of the year.

McDonough has held several leading positions within Genzyme in the US since 2002, beginning his career with the firm in corporate development.

‘Geoff is well-recognised for his solid and broad commercial and clinical expertise and for his background in the orphan drug and niche speciality market,’ said Bo Jesper Hansen, chairman of Sobi.

‘He will lead Sobi toward our vision of becoming the leading niche speciality pharmaceutical company in Europe.’

You may also like

Research & Development
Sobi Orfadin capsules approved in Saudi Arabia

Sobi Orfadin capsules approved in Saudi Arabia

Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Manufacturing

Sobi signs manufacturing agreements with Pfizer

Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Regulatory
Measurement uncertainty explained – Why it matters more than you think

Measurement uncertainty explained – Why it matters more than you think

In regulated environments, where decisions often depend on whether a result passes or fails a defined limit, understanding measurement uncertainty becomes critical
Pharmaceutical
MSD partners with Abu Dhabi to explore regional pharma logistics hub in HELM Cluster

MSD partners with Abu Dhabi to explore regional pharma logistics hub in HELM Cluster

The collaboration would strengthen supply chain resilience and accelerate access to innovative therapies across the region, subject to approvals, positioning Abu Dhabi as a secure distribution gateway for global pharma
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Neuland Laboratories announces new $20m process development lab in Hyderabad

Neuland Laboratories announces new $20m process development lab in Hyderabad

The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Subscribe now